Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited · As of May 2026 — confirm current pricing directly with the pharmacy or manufacturer.
Key Takeaways
- Cash retail Mounjaro: approximately $1,069/month in May 2026
- The Mounjaro Savings Card does not apply to uninsured patients
- Lilly Cares Foundation provides Mounjaro at $0 for qualifying uninsured patients with type 2 diabetes and income at or below 400% of FPL
- Lilly Direct's cash-pay vial program is for Zepbound only; there is no Mounjaro vial alternative
- Annual cash-pay Mounjaro: roughly $12,828 at retail; $0 with Lilly Cares approval
Direct answer
Brand Mounjaro costs approximately $1,069 per month at U.S. cash retail in May 2026. The Mounjaro Savings Card requires commercial insurance, so it does not help uninsured patients. The two real cash-reduction paths are the Lilly Cares Foundation Patient Assistance Program (free for qualifying low-income uninsured patients) and modest savings through GoodRx or SingleCare at participating pharmacies. There is no Mounjaro equivalent to Zepbound's Lilly Direct vial program. Confirm current pricing directly with the pharmacy or manufacturer.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- The cash price reality
- Why the Mounjaro Savings Card does not help uninsured patients
- Lilly Cares: the manufacturer's uninsured pathway
- Why there is no Mounjaro vial program
- Discount card economics
- The Zepbound conversation
- International tirzepatide considerations
- Annual cost projections
- Decision framework for cash-pay diabetes patients
- What we tell uninsured T2D patients on the platform
- FAQ
- Sources
The cash price reality
Mounjaro is priced at its wholesale acquisition cost near $1,069 per month. Pharmacy cash dispensing typically falls within $50 of WAC. Real cash quotes pulled from U.S. markets in May 2026 cluster between $1,005 and $1,115. Confirm current pricing directly with the pharmacy or manufacturer.
One monthly supply is four single-use autoinjector pens, one per week. Mounjaro is dispensed in 2.5, 5, 7.5, 10, 12.5, and 15 mg pen strengths. Cash pricing does not meaningfully vary across dose strengths.
Why the Mounjaro Savings Card does not help uninsured patients
Patients searching online for "Mounjaro coupon" routinely land on the Lilly Mounjaro Savings Card page. The card is appealing in design but inapplicable to uninsured patients. Eligibility requires:
- Active commercial insurance (not Medicare, Medicaid, TRICARE, or VA)
- The insurance covers Mounjaro for type 2 diabetes
- The patient has a Mounjaro prescription for that indication
Without commercial insurance, the card returns "not eligible" at activation. The discount is computed on top of an insurance copay; with no copay to discount, the card has no function.
This is the most common cost-confusion call our platform receives from prospective Mounjaro patients: they have heard about the savings card and assume it lowers cash prices. It does not.
Lilly Cares: the manufacturer's uninsured pathway
The Lilly Cares Foundation Patient Assistance Program provides Mounjaro at no cost to qualifying uninsured patients with type 2 diabetes. Eligibility as of May 2026:
| Requirement | Detail |
|---|---|
| Residency | U.S. citizen or legal resident |
| Income | At or below 400% of the federal poverty level |
| Insurance status | Uninsured or insured without prescription drug coverage that includes Mounjaro |
| Diagnosis | Prescription for FDA-approved indication (type 2 diabetes) |
| Documentation | Tax return or pay stubs, prescriber signature on application |
| Approval term | Typically 12 months, renewable |
| Cost | $0 if approved |
Approval timeline is four to eight weeks. The most common application failures: incomplete income documentation, prescription written for off-label weight loss rather than diabetes, or unclear insurance coverage status. Patients with insurance that "excludes" Mounjaro need to provide formal denial letters to qualify.
Why there is no Mounjaro vial program
Lilly Direct's manufacturer-direct vial program offers tirzepatide at $349-$499 per month, but the product sold through that channel is Zepbound, not Mounjaro. Lilly built the vial program specifically around the obesity indication. The vial NDC is registered as Zepbound.
Why does this matter? For an uninsured patient who has type 2 diabetes and needs tirzepatide, the molecule is identical. A clinician evaluating the case may consider whether the patient also meets criteria for Zepbound (BMI 30 or greater, or 27 with comorbidity such as the diabetes itself). If clinically appropriate, the patient could potentially access Lilly Direct vials by being prescribed Zepbound on the obesity indication.
This is a conversation for the prescriber. The molecule is the same; the label is what differs. Switching labels has clinical and prescribing implications that should be evaluated case by case.
Discount card economics
Discount cards offer modest help for cash Mounjaro patients:
| Card | Approximate Mounjaro price, May 2026 |
|---|---|
| No card | $1,069 average |
| GoodRx | $990 to $1,050 |
| SingleCare | $995 to $1,055 |
| Costco member | $960 to $1,020 |
| RxSaver | $1,000 to $1,055 |
Savings range from roughly 1 to 10 percent off retail. Helpful at the margin but not transformative.
The Zepbound conversation
For uninsured patients struggling with cash-pay Mounjaro, the Zepbound conversation is worth having with the clinician. Considerations:
- Same active ingredient (tirzepatide)
- Same dosing schedule and dose strengths
- Similar safety profile
- Different FDA-approved indication, which can change insurance coverage and patient assistance eligibility
- Different distribution channels, including Lilly Direct vials at $349-$499
A type 2 diabetes patient with a BMI of 30 or greater meets criteria for both Mounjaro and Zepbound. The clinician would document the indication choice based on the dominant clinical concern and the access pathway that makes treatment feasible.
International tirzepatide considerations
Tirzepatide is sold internationally under the Mounjaro brand. Personal importation from accredited Canadian or European pharmacies is technically a gray area in U.S. regulation. Real considerations:
- FDA Personal Importation Policy generally tolerates personal-use 90-day-or-less quantities with a valid prescription
- Customs seizure occurs but historically has been infrequent for small personal orders from accredited pharmacies
- Counterfeit Mounjaro has been documented in non-accredited online sellers; risk is high outside verified pharmacies
- Cold-chain integrity during international shipping is variable
- Adverse event reporting and clinical oversight are weaker when product is sourced abroad
For patients seriously considering this path, verified Canadian pharmacies (CIPA, PharmacyChecker) generally price Mounjaro at $300 to $450 monthly. The savings are real but bring the risks listed above.
Annual cost projections
| Path | Approximate monthly cost | Approximate annual cost |
|---|---|---|
| Cash retail | $1,069 | $12,828 |
| Cash retail with discount card | $960-$1,050 | $11,520-$12,600 |
| Lilly Cares (if approved) | $0 | $0 |
| Zepbound via Lilly Direct vials (if clinically appropriate) | $349-$499 | $4,188-$5,988 |
| International Mounjaro from accredited Canadian pharmacy | $300-$450 | $3,600-$5,400 |
Decision framework for cash-pay diabetes patients
Step 1: If income is at or below 400% of FPL, apply to Lilly Cares first. Approval = $0.
Step 2: If Lilly Cares is denied or you do not qualify, talk to the clinician about whether Zepbound is appropriate given any obesity comorbidity. Lilly Direct vials at $349-$499 may be accessible.
Step 3: If only Mounjaro is clinically appropriate, compare cash retail against Costco member pricing and discount cards. Expect $960 to $1,050 monthly.
Step 4: Consider whether older GLP-1 medications (such as semaglutide via Ozempic) or non-GLP-1 diabetes therapies (metformin combinations, SGLT2 inhibitors, basal insulin) are clinically appropriate at lower cost.
Step 5: International importation is a last-resort option with real risks.
What we tell uninsured T2D patients on the platform
The pattern we see with uninsured type 2 diabetes patients seeking Mounjaro:
Approximately 35 percent qualify for Lilly Cares and end up at $0 after a four-to-eight-week application process. We help them bridge with a Zepbound-indication path or alternative diabetes therapies if needed.
Approximately 30 percent meet criteria for Zepbound (BMI 30+, or 27+ with the diabetes itself) and access Lilly Direct vials. Their cost drops to $349-$499 monthly.
Approximately 20 percent pay cash retail with discount cards, often because Lilly Cares denied them on income and they prefer brand Mounjaro over alternatives.
The remaining 15 percent pursue alternative agents, international importation, or discontinuation. The right path is highly individual and best decided with the prescribing clinician.
FAQ
How much is Mounjaro without insurance? Approximately $1,069 per month at U.S. cash retail as of May 2026.
Is there a manufacturer program for uninsured Mounjaro patients? Yes, the Lilly Cares Foundation Patient Assistance Program. Free Mounjaro for qualifying low-income uninsured patients.
Does Lilly Direct offer Mounjaro cash-pay vials? No. Lilly Direct's vial program is for Zepbound, not Mounjaro.
Can I use GoodRx for Mounjaro? Yes, with modest savings of 5 to 10 percent at participating pharmacies.
Is compounded tirzepatide an option for uninsured diabetes patients? Most compounded tirzepatide is prescribed for weight management rather than diabetes. Discuss with your prescriber if interested.
How does cash-pay Mounjaro compare to cash-pay Ozempic? Mounjaro slightly higher (~$1,069 vs $998). Patient assistance programs are similar.
Can a Mounjaro prescription be filled internationally? Personal importation exists in a gray area; accredited Canadian pharmacies often price tirzepatide at $300-$450. Seizure and counterfeit risks apply.
What is the annual cost of cash-pay Mounjaro? Approximately $12,828 at retail; $0 with Lilly Cares approval.
Can I switch to a cheaper diabetes medication? Possibly. Older GLP-1s, SGLT2 inhibitors, and combination oral agents may be appropriate and cheaper. Talk to your prescriber.
What happens if I stop Mounjaro for cost reasons? Glycemic control often deteriorates over weeks to months without an effective replacement. Coordinate any stop with your clinician to avoid uncontrolled diabetes.
How fast does Lilly Cares approve? Four to eight weeks typically. Submit complete documentation to avoid delays.
Sources
- Eli Lilly and Company. Mounjaro Wholesale Acquisition Cost and Lilly Cares program documentation. Mounjaro.lilly.com. 2026.
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. 2024.
- U.S. Department of Health and Human Services. Federal Poverty Level Guidelines 2026. ASPE.
- FDA. Personal Importation Policy. Regulatory Procedures Manual.
- American Diabetes Association. Standards of Medical Care in Diabetes. 2026.
- Lilly Cares Foundation. Patient assistance program application. 2026.
- PharmacyChecker International Drug Price Comparison Database. 2026.
- GoodRx Research. Drug Price Trends Report. 2025.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- NeedyMeds. Lilly Cares and patient assistance program directory. 2026.
Footer disclaimers
Platform Disclaimer. FormBlends operates as a digital health platform connecting patients with licensed independent providers and partnered pharmacies. We do not manufacture, prescribe, or dispense medication. The treating clinician is responsible for all medical decisions based on individual evaluation.
Compounded Medication Notice. References to compounded tirzepatide describe products prepared by 503A state-licensed pharmacies under specific prescriptions. Compounded preparations are not FDA-approved and not interchangeable with brand Mounjaro or brand Zepbound.
Results Disclaimer. Dollar figures, eligibility criteria, and program terms cited reflect data available in May 2026. Manufacturer programs, formulary placements, and pharmacy retail are subject to change. Verify pricing and eligibility with the manufacturer or pharmacy before relying on these numbers.
Trademark Notice. Mounjaro, Zepbound, Lilly Direct, and Lilly Cares are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. GoodRx, SingleCare, and Costco are registered trademarks of their respective owners. FormBlends has no affiliation with any manufacturer or retailer named here.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →